Israeli start-up CytoReason – a leading developer of computational machine-learning models for drug development – announced the extension of its collaboration agreement with Pfizer, which began in 2019, on Thursday.
Read more here.
Israeli start-up CytoReason – a leading developer of computational machine-learning models for drug development – announced the extension of its collaboration agreement with Pfizer, which began in 2019, on Thursday.
Read more here.
![[Zoomcar in Financial Express] Zoomcar service review: How convenient is it for outstation self-drive travels](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
